METHODS: A total of 184 epilepsy patients were selected from the group of 10,152 HCV-infected patients treated for HCV infection within the Epiter-2 database from 2015 to 2018. Comparing the effectiveness and safety of anti-HCV regimens between the patients with comorbid epilepsy and 3573 patients without comorbidities was our study\'s objective.
RESULTS: The effectiveness of anti-HCV treatment was high in both the sample and the control group. No statistically significant SVR difference was observed between the sample group, with ITT = 93.5% and mITT = 95.5%, and the control group, with ITT = 95.2% and mITT = 97.5%, regardless of the genotype and the stage of liver disease at the start of therapy. The treatment was safe in patients with epilepsy.
CONCLUSIONS: The effectiveness and safety of HCV treatment in patients with epilepsy are comparable to those of patients with no significant comorbidities.
方法:从2015年至2018年在Epiter-2数据库中接受HCV感染治疗的10,152名HCV感染患者中选择了184名癫痫患者。我们的研究目的是比较合并癫痫患者和3573例无合并症患者抗HCV方案的有效性和安全性。
结果:在样本组和对照组中,抗HCV治疗的有效性都很高。样本组间SVR差异无统计学意义,ITT=93.5%,MITT=95.5%,和对照组,ITT=95.2%,MITT=97.5%,无论治疗开始时的基因型和肝病阶段。癫痫患者的治疗是安全的。
结论:HCV治疗癫痫患者的有效性和安全性与无明显合并症的患者相当。